Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancerPedro Nazareth Aguiar, Gilberto Lopes, Carmélia Maria Noia Barreto et al.|Einstein (São Paulo)|2019Cited by 19
A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitorsMariane Teodoro Fernandes, Pedro Nazareth Aguiar, Jacob J. Adashek et al.|Drugs in Context|2018Cited by 11
Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of FundingBárbara de Souza Gutierres, Auro del Giglio, Anderson Ruiz Simões et al.|Journal of Thoracic Oncology|2020Cited by 9